Prior to the launch of the ENCePP project, the European Medicines Agency held meetings with a number of representatives of the identified stakeholders. The following parties were consulted:

- HMA, Heads of Medicines Agencies
- CHMP, Committee for Medicinal Products for Human Use
- PhVWP-CHMP, Pharmacovigilance Working Party
- ISPE, International Society for Pharmacoepidemiology
- ISoP, International Society of Pharmacovigilance
- EACPT, European Association for Clinical Pharmacology and Therapeutics
- ISPOR, International Society for Pharmacoeconomics and Outcomes Research
- PCWP-CHMP, Working Party with Patients' and Consumers' Organisations
- HCP WG, (Health Care Professionals Working Group)
- Pharmaceutical industry (AstraZeneca, Novartis, GSK, Pfizer, EliLilly and EFPIA)
- DG Research - European Commission's Directorate-General for Research
- Pan-EU and international organisations, e.g.UK Clinical Research Network (UKCRN), European Group for Blood and Marrow Transplantation (EBMT), European Surveillance Network of Psoriasis (PSONET), European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR)